Unisom May Benefit From FDA Concerns About Rx Competitors – Chattem
This article was originally published in The Tan Sheet
Executive Summary
Chattem expects recent FDA concerns about the side effects of prescription sleep aids to offer a revenue boost to the Unisom line it recently acquired from Johnson & Johnson